Related Experiment Videos
Cyclosporine in inflammatory bowel disease
1The Mount Sinai Medical Center, 1751 York Avenue, New York, NY 10128, USA.
Current Gastroenterology Reports
|September 12, 2000
Summary
Cyclosporine effectively treats steroid-resistant inflammatory bowel disease, offering short- and long-term remission. This review covers its efficacy, toxicity, quality of life, and clinical use patterns.
Area of Science:
- Immunosuppressive therapy
- Gastroenterology
- Pharmacology
Background:
- Inflammatory bowel disease (IBD) poses challenges in steroid-resistant cases.
- Cyclosporine has emerged as a treatment option for refractory IBD.
- Decade-long research provides updated data on its use.
Purpose of the Study:
- To review current data on cyclosporine's efficacy in IBD remission.
- To assess short-term and long-term toxicity profiles.
- To evaluate quality of life and clinical practice patterns.
Main Methods:
- Systematic review of studies on cyclosporine in IBD.
- Analysis of short-term and long-term efficacy data.
- Review of toxicity, quality of life, and practice pattern data.
Main Results:
- Cyclosporine demonstrates effectiveness in achieving and maintaining IBD remission.
- Updated data confirm short-term and long-term efficacy.
- Toxicity and quality of life data are presented.
Conclusions:
- Cyclosporine is a valuable option for steroid-resistant IBD.
- Understanding its efficacy, safety, and use patterns is crucial.
- Further research may refine its application in IBD management.